secwatch.observer — SEC 8-K summary
======================================

Issuer:     Actinium Pharmaceuticals, Inc. (ATNM)
CIK:        0001388320
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001213900-23-013059
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Actinium announces positive Phase 3 SIERRA trial results for Iomab-B in r/r AML
-------------------------------------------------------------------------------

- Iomab-B met primary endpoint: 22% durable CR vs 0% control (p<0.0001).
- Event-free survival HR=0.22 (78% risk reduction, p<0.0001).
- Iomab-B doubled 1-year OS (26.1% vs 13.1%) and median OS (6.4 vs 3.2 months).
- Sepsis rate 4x lower (6.1% vs 28.6%); 100% engraftment in Iomab-B arm.
- Patients achieving dCR had 92% 1-year and 60% 2-year survival.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1388320/000121390023013059/0001213900-23-013059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1388320/000121390023013059/ea173990-8k_actinium.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-013059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer